Evidence map›Paper›PMID 34325596›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2021

Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and

Mohammed M Alanazi, Elwan Alaa, Nawaf A Alsaif, Ahmad J Obaidullah, Hamad M Alkahtani, Abdulrahman A Al-Mehizia, Sultan M Alsubaie, Mohammed S Taghour, Ibrahim H Eissa

Open access · goldAbstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 50 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Design, synthesis, antitumor evaluation, and molecular docking of novel pyrrolo[2,3-d]pyrimidine as multi-kinase inhibitors.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  10. Angiogenic signaling pathways and anti-angiogenic therapy for cancer.Signal transduction and targeted therapy · 2023
    Review
  11. Article
  12. Article
  13. Article
  14. Design, synthesis and molecular docking of new fused 1Journal of enzyme inhibition and medicinal chemistry · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Mohammed M AlanaziDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0002-0483-8113
Elwan AlaaPharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.ORCID https://orcid.org/0000-0003-4270-616X
Nawaf A AlsaifDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0001-9215-1380
Ahmad J ObaidullahDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0002-7532-6318
Hamad M AlkahtaniDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0002-6983-8587
Abdulrahman A Al-MehiziaDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0002-6824-0137
Sultan M AlsubaieDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Mohammed S TaghourPharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.ORCID https://orcid.org/0000-0003-0630-709X
Ibrahim H EissaPharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.ORCID https://orcid.org/0000-0002-6955-2263
King Saud University · SAAl-Azhar University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is an urgent need to design new anticancer agents that can prevent cancer cell proliferation even with minimal side effects. Accordingly, two new series of 3-methylquinoxalin-2(1

Indexed as

AnimalsAntineoplastic AgentsApoptosisCell CycleCell Line, TumorCell ProliferationComputer SimulationDrug DiscoveryDrug Screening Assays, AntitumorHumansMolecular Docking SimulationQuinoxalinesRatsStructure-Activity RelationshipVascular Endothelial Growth Factor Receptor-2Antineoplastic AgentsKDR protein, humanQuinoxalinesVascular Endothelial Growth Factor Receptor-23-methylquinoxalin-2(1H)-one3-methylquinoxaline-2-thiolAnticancerapoptosisin silico studiesVEGFR-2 inhibitors

Identifiers

PMID34325596
PMCPMC8330740
OpenAlexW3186877437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.